+ Site Statistics
References:
52,654,530
Abstracts:
29,560,856
PMIDs:
28,072,755
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Treatment of Huntingtons disease with ethyl-eicosapentaenoic acid A randomized, placebo-controlled trial



Treatment of Huntingtons disease with ethyl-eicosapentaenoic acid A randomized, placebo-controlled trial



Journal of Molecular Neuroscience 16(2-3): 328-329, April-June




(PDF emailed within 1 workday: $29.90)

Accession: 035980502

Download citation: RISBibTeXText


Related references

Ethyl-eicosapentaenoic acid treatment in Huntington's disease: A placebo-controlled clinical trial. Movement Disorders 30(10): 1426-1429, 2016

Ethyl-eicosapentaenoic acid in first-episode psychosis: a randomized, placebo-controlled trial. Journal of Clinical Psychiatry 68(12): 1867-1875, 2007

Ethyl-eicosapentaenoic acid for the treatment of psychological distress and depressive symptoms in middle-aged women: a double-blind, placebo-controlled, randomized clinical trial. American Journal of Clinical Nutrition 89(2): 641-651, 2009

Randomized, placebo-controlled study of ethyl-eicosapentaenoic acid as supplemental treatment in schizophrenia. American Journal of Psychiatry 159(9): 1596-1598, 2002

Effects of ethyl-eicosapentaenoic acid omega-3 fatty acid supplementation on hot flashes and quality of life among middle-aged women: a double-blind, placebo-controlled, randomized clinical trial. Menopause 16(2): 357-366, 2008

Randomized controlled trial of ethyl-eicosapentaenoic acid in Huntington disease: the TREND-HD study. Archives of Neurology 65(12): 1582-1589, 2008

Treatment of psoriasis with eicosapentaenoic acid a double blind randomized placebo controlled trial. Annali Italiani di Dermatologia Clinica e Sperimentale 43(2): 131-139, 1989

Ethyl-eicosapentaenoate in Huntingtons Disease A randomised, placebo-controlled Trial. Neurology 60(5 Supplement 1): A246-A247, March 11, 2003

Eicosapentaenoic Acid Ethyl Ester AMR11 Therapy in Patients With Very High Triglyceride Levels from the Multi-center, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension MARINE Trial. 2011

Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from the Multi-center, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension [MARINE] trial). American Journal of Cardiology 108(5): 682-690, 2011

A placebo-controlled trial of omega-3 fatty acid (ethyl eicosapentaenoic acid) supplementation for residual symptoms and cognitive impairment in schizophrenia. American Journal of Psychiatry 158(12): 2071-2074, 2001

The effects of eicosapentaenoic acid in tardive dyskinesia: a randomized, placebo-controlled trial. Schizophrenia Research 84(1): 112-120, 2006

Safety of the omega-3 fatty acid, eicosapentaenoic acid in psychiatric patients results from a randomized, placebo-controlled trial. Psychiatry Research1: 3, 284-291, 2008

Safety of the omega-3 fatty acid, eicosapentaenoic acid (EPA) in psychiatric patients: results from a randomized, placebo-controlled trial. Psychiatry Research 161(3): 284-291, 2008

Eicosapentaenoic acid versus docosahexaenoic acid in mild-to-moderate depression: a randomized, double-blind, placebo-controlled trial. European Neuropsychopharmacology 23(7): 636-644, 2014